PT Merck Tbk

As of June 30, 2026, PT Merck Tbk carries a market capitalization of 1.61T, placing it among publicly traded companies globally. Its enterprise value stands at 1.30T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, PT Merck Tbk has 448.00M shares outstanding.

As of June 30, 2026, PT Merck Tbk trades at a trailing price-to-earnings ratio of 4.84. The price-to-sales ratio is 1.19, and the price-to-book ratio stands at 1.67.

As of June 30, 2026, PT Merck Tbk trades at an EV/EBITDA multiple of 2.97 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 3.02 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.30T versus a market cap of 1.61T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, PT Merck Tbk maintains a current ratio of 5.00, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.81, indicating elevated leverage, while an interest coverage ratio of 188.52 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, PT Merck Tbk posted a return on equity (ROE) of 37.14, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 34.30 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 29.81, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 36.62, useful for judging operating efficiency across full business cycles. The company generates approximately 3.68B in revenue per employee across its workforce of 367.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.03 indicates how many times PT Merck Tbk sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PT Merck Tbk recorded 114.67B in income tax expense. That works out to an effective tax rate of 25.61, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 447.83B, leaving 333.16B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, PT Merck Tbk's stock has gained approximately 34.88% over the past 52 weeks. The 50-day moving average sits at 3,814.60, while the 200-day moving average is 3,622.30.

Over the twelve months ended June 30, 2026, PT Merck Tbk generated 1.35T in revenue and converted that into 333.16B in net income, yielding earnings per share of 743.66. EBITDA reached 439.19B, while operating income came in at 431.14B.

As of June 30, 2026, PT Merck Tbk holds 328.00B in cash and equivalents against 17.46B in total debt, resulting in a net debt position of -328.00B. Total book value stands at 964.29B, with working capital of 809.59B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, PT Merck Tbk posted a gross margin of 49.96, reflecting its pricing power and cost economics. The operating margin of 31.92 and net profit margin of 24.67 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, PT Merck Tbk paid dividends of 169.19 per share. The dividend payout ratio of 22.75 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 12.93, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PT Merck Tbk shareholders.

PT Merck Tbk's most recent stock split took place on December 21, 2015 with a 1:20 split ratio.

As of June 30, 2026, PT Merck Tbk has an Altman Z-Score of 7.78, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.